undamentalytics Newsletter
Sign in

Hutchmed (china) Ltd income statement

In fiscal 2025, Hutchmed (china) Ltd reported revenue of $549m, down 13.0% on the year before, operating income of −$39.2m (a -7.1% margin) and net income of $457m, or $2.60 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue87178216241214205228356426838630549
Cost of revenue————————311384349336
Gross profit————————115454281212
Research and development30476776114138175299387302212148
General and administrative132022243139508992806467
Operating income−18−10−47−53−93−146−197−328−40818−44−39
Interest expense212111111133
Income before tax−31321−54−87−141−190−216−41058−1499
Income tax124343512−05764
Net income−7812−27−75−106−126−195−36110138457
Diluted EPS——$0.10−$0.21−$0.56−$0.80−$0.90−$1.25−$2.15$0.60$0.20$2.60
Diluted shares (average)105m109m120m123m133m133m140m159m169m174m175m175m
EBITDA−17−8−44−51−89−141−191−321−39927−31−26

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ADMA vs HCMHCM vs TARSHCM vs MIRM

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Hutchmed (china) Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Hutchmed (china) Ltd.